A study involving 16 million people in the US found that those prescribed so-called GLP-1-agonists had an increased risk of serious gastrointestinal conditions, including stomach paralysis
– have a higher risk of developing rare but serious gastrointestinal conditions, including stomach paralysis. That’s the conclusion of an analysis of the side effects associated with the weight loss medications.which work by mimicking a hormone – GLP-1 – that encourages us to feel satiated after eating. Both drugs contain a so-called GLP-1 agonist, semaglutide, as their active ingredient. Similar drugs contain different GLP-1 agonists, including one named liraglutide.
semaglutide or liraglutide during this period. None of them had diabetes, which suggests they were given the drug for off-label use – presumably to help them lose weight. These findings suggest that GLP-1 agonists, such as Ozempic and Wegovy, may heighten the risk of serious gastrointestinal conditions. People must be made aware of these risks, rare though they are, especially given the
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight Loss Drugs Ozempic and Wegovy Linked to Severe Gut Problems: StudyA small percentage of users may experience severe gastrointestinal side effects.
Read more »
Ozempic, Wegovy linked to severe medical conditions including stomach problems, study findsBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Ozempic and Wegovy linked to gastrointestinal problems in new researchGabrielle M. Etzel is the healthcare policy reporter for the Washington Examiner. Prior to joining the Washington Examiner, she served as a staff reporter at Campus Reform and as a freelance writer. After graduating from Grove City College, Etzel earned her master's in public policy and administration from Baylor University, where she conducted research on domestic sex trafficking. In her free time, Etzel enjoys being with her family in Pittsburgh, Pennsylvania.
Read more »
Novo Nordisk's Wegovy bonanza looms large in DenmarkThe whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk (NOVOb.CO), but also for its home country of Denmark.
Read more »
Nestle shares at two-year low as investors weigh Wegovy rolloutNestle shares at two-year low as investors weigh Wegovy rollout
Read more »
Nestle shares at two-year low as investors weigh Wegovy rolloutNestle (NESN.S) shares were under pressure on Friday as investors weighed the potential impact of Novo Nordisk's (NOVOb.CO) blockbuster weight-losing drug Wegovy and how it could reduce spending on food.
Read more »